She obtained her Ph.D. in Pharmacology from King's College, London in 1981, and since then the primary focus of her work has been cardiomyocyte function in the failing heart. This has extended to gene therapy to modulate cardiomyocyte function, and she is Scientific PI for the UK's first clinical trial on myocardial gene therapy. More recently the scope has extended to the characterisation of cardiomyocytes derived from embryonic stem cells, and their use in cardiac repair, tissue engineering and drug discovery.
Professor Harding is Past-President of the European Section of the International Society for Heart Research and Fellow of the AHA, ESC and ISHR. She sits on the Nuffield Council on Bioethics and the Scientific Advisory Board of the PPP "Stem Cells for Safer Medicines".
Professor Harding delivered her Inaugural Lecture, entitled 'Reviving the Failing Heart: one cell at a time', on 3 April 2007. The abstract and other details of the lecture can be found here.
et al., 2019, Proteomic Analysis Reveals Temporal Changes in Protein Expression in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes In Vitro., Stem Cells Dev
et al., 2019, MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo., Cell Stem Cell
et al., 2019, Ventricular conduction stability test: a method to identify and quantify changes in whole heart activation patterns during physiological stress., Europace
Sattler S, Couch LS, Harding SE, 2018, Takotsubo Syndrome: Latest Addition to the Expanding Family of Immune-Mediated Diseases?, Jacc Basic Transl Sci, Vol:3, Pages:779-781
et al., 2018, Isogenic Pairs of hiPSC-CMs with Hypertrophic Cardiomyopathy/LVNC-Associated ACTCI E99K Mutation Unveil Differential Functional Deficits, Stem Cell Reports, Vol:11, ISSN:2213-6711, Pages:1226-1243